UK Ophthalmic Drugs Market Insight
Published: 29 May 2026 | Report Format: Electronic (PDF)
The UK ophthalmic drugs market size is rapidly expanding, at a 5.82% CAGR, and the glaucoma therapies, retinal treatments, biologics, and ageing population demand.
UK Ophthalmic Drugs Market Insights Forecasts to 2035
- The UK Ophthalmic Drugs Market Size Was Estimated at USD 2.21 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.82% from 2025 to 2035
- The UK Ophthalmic Drugs Market Size is Expected to Reach USD 3.89 Billion by 2035
Notable Insights for UK Ophthalmic Drugs Market
- Anti-glaucoma medications have almost 32% market share in the United Kingdom ophthalmic drug industry due to high prevalence of glaucoma and intraocular pressure management, which is supported by NHS Eye Care Services having investments of about £1.7billion in eye care treatments.
- There is a demand for therapies for retinal disorders in the United Kingdom that stands at around 28% owing to diabetic retinopathy and macular degeneration, which is being backed by RNIB having investments of about £2.3billion in advanced retinal care and biologic ophthalmology treatments.
- The United Kingdom's health care industry invests over £190billion annually, leading to growth in treatments related to eye diseases and biologics, which is being supported by Department of Health and Social Care UK making investments of about £5.4billion in eye health care modernization.
- Treatments for dry eye disease constitute close to 21% demand share in the United Kingdom owing to screen usage and aging of population, which is being aided by College of Optometrists UK making investments of about £1.2billion in ocular treatment.
Download the eBook (ToC)
Why Buy This Report
- Obtain complete information on the UK market for eye drugs including anti-glaucoma eye drugs, retina biologics, drugs for dry eye syndrome, ocular anti-inflammatory drugs, and sustained release ophthalmic drugs delivery systems.
- Get to know how artificial intelligence-enabled diagnostics, precision eye treatments, biologic eye medicines, gene-based eye treatments, and digital health innovations are revolutionizing the UK ophthalmic drugs market.
- Learn about potential investments in eye disease treatments, biologics for eye disease treatments, ocular drug delivery system technology, precision eye treatment systems, and ophthalmic treatment infrastructure.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the UK ophthalmic drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Ophthalmic Drugs Market
-
- Novartis
- Roche
- AbbVie
- Bausch + Lomb
- Alcon
- Santen Pharmaceutical
- Pfizer
- Bayer
- Others
Recent Developments:
- In April 2026, Roche strengthened the United Kingdom ophthalmic drugs market through Vabysmo retinal therapies and AI-powered OCT diagnostics, supported by CHF 1.024 billion ($1.3 billion) Vabysmo Q1 2026 sales, advancing AMD, DME, RVO, and precision retinal disease management.
- In October 2025, Novartis strengthened the United Kingdom ophthalmic drugs market through Beovu biologic retinal therapies and long-acting ocular technologies, supported by $3.2 billion ophthalmology revenues, enhancing AMD treatment efficiency, personalized eye care, and retinal disease management across European healthcare markets.
Market Segmentation:
United Kingdom Ophthalmic Drugs Market, By Drug Class
- Anti-Glaucoma Drugs
- Anti-Inflammatory Drugs
- Anti-Infective Drugs
- Retinal Disorder Therapies
- Dry Eye Medications
- Others
United Kingdom Ophthalmic Drugs Market, By Disease Indication
- Glaucoma
- Cataracts
- Dry Eye Disease
- Retinal Disorders
- Eye Infections
- Others
United Kingdom Ophthalmic Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Others
United Kingdom Ophthalmic Drugs Market, By End User
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Expert Views:
The United Kingdom ophthalmic drugs market is anticipated to experience impressive growth in the coming years due to growing incidences of chronic eye diseases, increasing aging population, and investments in next-generation ophthalmology treatment technologies.
Author: Govind and Krishna By Spherical Insights and Consulting